Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer

Doo Yong Chung, Hyeok Jun Goh, Dong Hoon Koh, Min Seok Kim, Jong Soo Lee, Won Sik Jang, Young Deuk Choi

Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea

Abstract

Purpose

The aim of this study was to evaluate predictors of residual tumor and clinical prognosis in T1a-T1b (incidental) prostate cancer by analysis of specimens from men undergoing surgery for benign prostatic hyperplasia.

Materials and methods

We retrospectively reviewed medical records of incidental prostate cancer patients who had undergone radical prostatectomy. Patients whose tumor statuses were further confirmed by prostate biopsy, or who had used androgen deprivation therapy before radical prostatectomy, were excluded. Clinical and pathological parameters were analyzed to evaluate residual tumor and clinical prognosis. We used univariate and multivariate logistic regression analyses, as well as receiver operator characteristics, to predict residual tumor (pT0).

Results

The final analysis included 95 patients. Among these patients, 67 (70.53%) exhibited residual tumor, whereas 28 (29.47%) did not (pT0). Pathology findings showed that 44 (65.67%), 16 (23.88%), and 7 patients (10.45%) exhibited Gleason scores of G6, G7, and ≥G8, respectively. Fifty-seven and 10 patients exhibited pathologic T stages T2 and T3, respectively. Mean follow-up duration was 70.26 (±34.67) months. Biochemical recurrence was observed in 11 patients; none were pT0 patients. Multivariate logistic regression showed that low prostate-specific antigen density after benign prostatic hyperplasia surgery and invisible lesion on multiparametric magnetic resonance imaging were significantly associated with pT0. Additionally, a combination of these factors showed an increase in the diagnostic accuracy of pT0, compared with mpMRI alone (AUC 0.805, 0.767, respectively); this combination showed sensitivity, specificity, and positive predictive values of 71.6%, 89.3%, and 94.1%, respectively.
Conclusion

Our results suggest that patients with incidental prostate cancer who have both prostate-specific antigen density ≤0.08 after benign prostatic hyperplasia surgery as well as invisible cancer lesion on multiparametric magnetic resonance imaging should be considered for active surveillance.

Introduction

Prostate cancer (PCa) is one of the most prevalent cancers worldwide; moreover, it exhibits the highest incidence among all cancers in males in the United States, especially in elderly individuals [1]. As PCa screening through measurement of prostate-specific antigen (PSA) levels has become more widespread, the proportion of PCa patients presenting with low-risk factors has also increased [2]. According to the European Association of Urology guidelines, an extended 12-core systematic transrectal ultrasound (TRUS)-guided biopsy should be performed for patients with an elevated PSA level; this is endorsed as the optimal biopsy method [3]. Therefore, in the PSA era, most cases of PCa are found by prostate biopsy; the number of prostate cancers found by benign prostatic hyperplasia (BPH) surgery is reportedly decreasing [4]. However, during BPH surgery, PCa was found incidentally in 5–13% of patients who did not have a prior diagnosis [5,6]. According to the TNM staging system, the presence of incidental PCa (IPCa) in less than 5% of resected prostate tissue is classified as clinical stage T1a; its presence in more than 5% of resected tissue is classified as T1b. Although most cases of IPCa are considered clinically insignificant, recent studies have suggested that in some cases, the prognosis may become more unfavorable [7]. Therefore, controversies exist regarding the most appropriate management for patients diagnosed with IPCa. Several guidelines suggest radical prostatectomy (RP) as treatment for patients with a life expectancy of more than 10 years [3].

Notably, the probability of finding no residual cancer (pT0) among patients with IPCa who undergo RP has been reported in several studies [5,8–10]. In patients with IPCa, the vanishing cancer phenomenon is more likely to be related to the presence of a small cancer that can be entirely removed during initial surgery [11]. If pT0 can be predicted by preoperative assessment of patients with IPCa, overtreatment may be avoided. Previous studies have used factors such as PSA and Gleason score (GS) to evaluate the significance of IPCa. Recently, there has been a rapid increase in the use of multiparametric magnetic resonance imaging (mpMRI) for diagnosis and staging of PCa. Therefore, in this study, we evaluated whether pT0 could be predicted in patients with IPCa by using preoperative diagnostic tools, including mpMRI.

Materials and methods

Study design and patients

We retrospectively reviewed the clinical and pathological data of 107 individuals with PCa who underwent BPH surgery before RP at our institution between June 2006 and December 2016; patients whose tumor statuses were further confirmed by prostate biopsy during surgery for BPH, or who had used androgen deprivation therapy before RP, were excluded. Therefore, 95 patients were included in this analysis; all included patients underwent mpMRI before RP. All images were retrospectively reviewed by three experienced uroradiologists who were blinded to pathologic results; they conducted a consensus review of the mpMRI images of all patients. The mpMRI images included standardized criteria for Likert scoring of multiparametric sequences using a 3.0-T MRI system (Intera Achieva 3.0-T, Phillips Medical System,
Best, The Netherlands) [12]. From 2006 to 2009, mpMRI included T1-weighted [T1W] and T2-weighted [T2W] imaging, as well as dynamic contrast-enhanced imaging [DCE]. Diffusion-weighted imaging [DWI] and the apparent-diffusion coefficient [ADC] have been added since 2010. In mpMRI, suspicious lesions were graded 1–5 by using a scoring system established by the Prostate Imaging Reporting and Data System (PI-RADS) [13,14]. Negative MRI findings were defined as the absence of grade 3 or higher regions of interest (ROIs) [15,16]. We also excluded patients with limitations with regard to interpretation by the radiologists due to mpMRI without DWI and ADC. PI-RADS\(^{\text{V2}}\) was used as a standard when the image was reviewed again by radiologists. Clinical characteristics of these patients included age, body mass index, PSA before and after BPH surgery, and prostate volume (measured by TRUS) before and after BPH surgery [17]. In addition, Gleason score (GS), resection volume, and tumor volume following BPH surgery, as well as pathologic characteristics of specimens following RP, were obtained. All pathologic diagnoses were performed by expert pathologists. Finally, TNM stage was determined in accordance with the 8th edition of the American Joint Committee on Cancer TNM staging system.

**Follow-up**

Postoperative PSA follow-up was performed monthly for the first 6 months, every 3 months for the second year, and every 6 months thereafter. Biochemical recurrence (BCR) was defined as any two consecutive increases in serum PSA \(\geq 0.2\) ng/ml following RP [18]. BCR-free survival was defined as the time from RP to BCR. The follow-up period was calculated from the date of RP to the date of the last known contact with the patient.

**Research involving human participants and/or animals**

All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. Data were collected after approval from the Institutional Review Board at Yonsei University College of Medicine (protocol number 4-2018-0669).

**Informed consent**

Informed consent was not required from individual participants included in the study due to its retrospective design involving review of medical records.

**Statistical analysis**

We compared clinical and pathological characteristics between groups by using Mann–Whitney U tests for continuous data and \(\chi^2\) tests for dichotomous variables. Univariate and multivariate logistic regression analysis were performed to assess the association between baseline parameters and residual cancer. Significant variables from univariate analysis were included in the multivariate analysis. Moreover, the Kaplan-Meier method, combined with log-rank tests, was performed to estimate and compare oncologic outcomes with respect to pT0. Receiver operator characteristic (ROC) curve analysis was performed to determine the optimal cut-off value via the area under the curve (AUC). Comparisons where \(p < 0.05\) were considered statistically significant. These statistical analyses were performed with SPSS Statistics software, version 23.0 (IBM, Armonk, NY, USA). In addition, assessments of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% confidence intervals were performed with Medcalc (version 18.3; Mariakerke, Belgium).
Results

Patient and disease characteristics
A total of 95 incidental PCa patients were included. At the time of surgery for BPH, patients were classified as stage T1a (n = 49) or T1b (n = 46), in accordance with the 8th edition of the American Joint Committee on Cancer TNM staging system. The mean age for all patients was 67.31 ± 4.93 years. The mean prostate volume, as measured by TRUS, was 39.88 ± 16.97 ml; the mean PSA and PSA density values were 4.45 ± 3.63 ng/ml and 0.13 ± 0.14 ng/ml², respectively. The mean resection volume was 11.17 ± 10.35 ml; the mean PSA and PSA density values after BPH surgery were 1.58 ± 1.40 ng/ml and 0.06 ± 0.06 ng/ml². Among specimens following BPH surgery, 75 exhibited GS 6 (76.1%), 13 exhibited GS 7 (17.4%), and 7 exhibited GS ≥8 (6.6%). Forty-nine patients (51.6%) showed no suspicious lesions during MRI performed to evaluate the presence of PCa. Of the 46 patients (48.4%) with suspicious lesions, 33 showed lesions in the peripheral zone, 9 showed lesions in the transitional zone, and 4 showed lesions in both the peripheral and transitional zones.

The median follow-up from RP was 68.37 ± 41.83 months. Among specimens following RP, 67 (70.53%) exhibited residual tumor and 28 (29.47%) did not (pT0). When dividing the two groups on the basis of residual tumor, there were significant differences between the two groups in PSA after BPH surgery, PSA density before and after BPH, and suspicious lesions in MRI. T stage, according to BPH surgery and PSA before BPH surgery, did not significantly differ between the two groups (Table 1).

Oncologic outcomes following RP
Among 67 RP specimens (excluding those with pT0), 44 exhibited GS 6 (65.7%) and 16 exhibited GS 7 (23.9%). Furthermore, GS ≥8 was present in 7 (10.4%). The median tumor volume of specimens following RP was 0.76 ± 1.1 ml. Pathologic stage ≥T3 was recorded in 10 cases (14.9%). Extracapsular extension (ECE) was present in 10 cases (14.9%); surgical margins were involved in 4 (6.0%). Invaded seminal vesicles were observed in 1 case (1.5%). Perineural invasion was reported in 1 case (1.5%); lymphovascular invasion (LVI) and lymph node metastasis were not reported. During the follow-up period, BCR was not observed in pT0 patients; in the residual PCA group, BCR was observed in 11 cases (16.4%). Furthermore, there were no cancer-specific deaths during the observation period (Table 2). Additionally, Kaplan-Meier curves showed a significant increase in BCR-free survival in the pT0 group (log-rank test, p = 0.027) (Fig 1). Univariate and multivariate Cox regression analyses were performed with each clinical parameter for BCR in patients with residual cancer. In these analyses, GS ≥8 (HR 18.235, p = 0.001) and pathologic T stage ≥T3 (HR 13.899, p < 0.001) were independent prognostic factors for BCR. In contrast, PSA, PSA density, and T1a or T1b were not statistically different.

Preoperative factors in relation to pT0 PCa
In this study, we used univariate and multivariate logistic regression analyses to identify predictors associated with pT0 PCa. In these analyses, PSA density after BPH surgery (Odds ratio [OR]: 0.684, 95% confidence interval [CI]: 0.469–0.997, p = 0.048) and suspicious lesion on mpMRI (OR: 11.827, 95% CI: 3.013–45.073, p = 0.001) constituted independent predictors of the presence of residual cancer at RP in both univariate and multivariate models. After BPH surgery, invisible lesion on mpMRI and low PSA density showed a significant correlation with pT0 (Table 3).
Table 1. Baseline patient characteristics.

| Variable                        | Total | Residual tumor | No_Residual tumor | p value |
|--------------------------------|-------|---------------|------------------|---------|
| N = 95 | SD | N = 67 (70.53%) | SD | N = 28 (29.47%) | SD |
| Age, years | 67.31 | 4.93 | 67.67 | 4.77 | 66.43 | 5.28 | 0.264 |
| BMI, kg/m² | 24.12 | 2.68 | 23.58 | 2.48 | 25.42 | 2.75 | 0.002 |
| PSA level before BPH surgery, ng/ml | 4.45 | 3.63 | 4.79 | 3.87 | 3.64 | 2.89 | 0.163 |
| PSA density before BPH surgery, ng/ml² | 0.13 | 0.14 | 0.15 | 0.16 | 0.08 | 0.06 | 0.005 |
| PSA level after BPH surgery, ng/ml | 1.58 | 1.40 | 1.82 | 1.47 | 1.01 | 1.00 | 0.003 |
| PSA density after BPH surgery, ng/ml² | 0.06 | 0.06 | 0.07 | 0.06 | 0.03 | 0.02 | <0.001 |
| Prostate volume, ml | 39.88 | 16.97 | 38.19 | 15.79 | 43.91 | 19.22 | 0.135 |
| Resection volume, ml | 11.17 | 10.35 | 10.47 | 10.04 | 12.98 | 11.05 | 0.273 |
| Duration between operations, days | 146.19 | 193.76 | 151.12 | 214.80 | 134.39 | 133.11 | 0.703 |
| Suspicious lesion on MRI | N | % | N | % | N | % | <0.001 |
| Yes | 46.00 | 48.42 | 43.00 | 64.18 | 3.00 | 10.71 |
| No | 49.00 | 51.58 | 24.00 | 35.82 | 25.00 | 89.29 |
| Gleason score | N | % | N | % | N | % | |
| 6 (ISUP G1) | 75.00 | 78.95 | 51.00 | 76.12 | 24.00 | 85.71 |
| 7 (ISUP G2) | 4.00 | 4.97 | 4.00 | 5.97 | 0.00 | 0.00 |
| ISUP G3 | 9.00 | 4.21 | 7.00 | 10.45 | 2.00 | 7.14 |
| ≥8 (ISUP G4) | 7.00 | 7.37 | 5.00 | 7.46 | 2.00 | 7.14 |
| Stage | N | % | N | % | N | % | 0.545 |
| T1a | 49.00 | 51.58 | 31.00 | 46.27 | 18.00 | 64.29 |
| T1b | 46.00 | 51.58 | 36.00 | 53.73 | 10.00 | 35.71 |
| FU duration after RP, months | 68.37 | 41.83 | 71.54 | 36.16 | 70.26 | 34.67 | 0.874 |

BMI, body mass index; PSA, prostate-specific antigen; BPH, benign prostatic hyperplasia; ISUP, International Society of Urological Pathologists; RP, radical prostatectomy; FU, follow-up

https://doi.org/10.1371/journal.pone.0210037.t001

Diagnostic accuracy for pT0 of mpMRI and PSA density after BPH surgery
The AUCs of the ROC curve for mpMRI and PSA density after BPH surgery were 0.767 (95% CI, 0.668–0.867) and 0.711 (95% CI, 0.602–0.820), respectively. Diagnosis of pT0 with mpMRI alone revealed sensitivity of 64.2% (95% CI, 51.5–75.5), specificity of 89.3% (95% CI, 71.8–97.7), PPV of 93.5% (95% CI, 82.9–97.7), and NPV of 51.0% (95% CI, 42.4–59.5). We enhanced the diagnostic accuracy of mpMRI by adding PSA density values. Notably, PSA density <0.08 showed the best correction value. The AUC of the ROC curve for this combination of predictive factors was 0.805 (95% CI, 0.711–0.879). Diagnosis of pT0 with the combined predictors revealed sensitivity of 71.7% (95% CI, 59.3–82.0), specificity of 89.3% (95% CI, 71.8–97.7), PPV of 94.1% (95% CI, 84.4–97.9) and NPV of 56.8% (95% CI, 46.8–66.3) (Fig 2) (Table 4).

Discussion
pT0 is a well-known rare phenomenon, occurring in <1% of all patients who undergo RP for PCa [19]. This is strongly associated with neoadjuvant therapy [20]. However, pT0 after RP in
IPCa exhibits a different incidence pattern; pT0 in IPCa patients without neoadjuvant therapy should be considered as complete resection of cancer by initial surgery for BPH treatment. Several studies have reported the prevalence of pT0 cases in patients with T1a–T1b treated with RP; these range from 2% to 48% in patients without previous neoadjuvant therapy [5,8–10,21]. However, there have been few studies to predict pT0. A study regarding prediction of residual tumors by Capitanio et al. [11] was published in 2010. Of 158 cases, T0 was found in 22; PSA before and after BPH operation was significant associated with pT0. However, univariate statistics were used in that study univariate; multivariate analyses were not performed. Similar to that study, postoperative PSA was a significant factor in univariate analyses in our study. In multivariate statistics, however, it was not significant. Therefore, we included PSA density before and after BPH surgery [22–24]; we found that the PSA density was a significant predictor of pT0 in IPCa. In our study, PSA density after BPH surgery was significant both in univariate and multivariate analyses. In addition, our prediction of pT0 was based on mpMRI performed after BPH surgery. To standardize the evaluation and reporting of prostate MRI, the European Society of Urogenital Radiology published guidelines based on an expert consensus in 2012 (PI-RADS). These guidelines were updated to PI-RADS version 2 in 2015 [13,14]. Notably, there is a growing role for mpMRI in the diagnosis of PCa. Therefore, we used a significant lesion on mpMRI as a predictor of pT0 in patients with IPCa; this yielded statistically significant results in our study. However, in many studies, a clinically significant lesion is present, although it remains invisible on mpMRI. Therefore, mpMRI is not a definite factor for

Table 2. Characteristics of patients with residual tumor following radical prostatectomy.

| Variable | Total |
|----------|-------|
|          | N = 67 |
| Pathologic Gleason score | N % |
| N | 6 (ISUP G1) | 44 | 65.67 |
| 7 (ISUP G2) | 13 | 19.40 |
| (ISUP G3) | 3 | 4.48 |
| \( \geq 8 \) (ISUP G4) | 7 | 10.45 |
| Tumor volume, ml | 0.76 | 1.10 |
| Pathologic T stage | N % |
| N | \( \leq T2 \) | 57 | 85.07 |
| \( \geq T3 \) | 10 | 14.93 |
| ECE | N % |
| 10 | 14.93 |
| SVI | N % |
| 1 | 1.49 |
| PSM | N % |
| 4 | 5.97 |
| LVI | N % |
| 0 | 0.00 |
| PNI | N % |
| 1 | 1.49 |
| BCR | N % |
| 11.00 | 16.42 |

ISUP, International Society of Urological Pathologists; ECE, extracapsular extension; SVI, seminal vesicle invasion; LVI, lymphovascular invasion; PSM, positive surgical margin; PNI, perineural invasion; BCR, biochemical recurrence

https://doi.org/10.1371/journal.pone.0210037.t002
determining the presence of residual tumor. In our study, 49 patients (51.58%) with IPCa exhibited invisible lesions on mpMRI; 24 of them had residual cancer after RP. Of these 24 patients, 6 exhibited G7, 2 exhibited T3 pathology, and 2 exhibited BCR during the follow-up period. Therefore, IPCa patients with invisible lesion on mpMRI may exhibit a clinically significant oncologic outcome. We believe it is difficult to use mpMRI alone as a method to predict pT0; thus, we added PSA density after BPH surgery, which was significantly associated with pT0, to increase the diagnostic accuracy of our predictive approach. When mpMRI and PSA density after BPH surgery were combined, the diagnostic accuracy of pT0 was improved, compared with mpMRI alone. We believe this may constitute a good diagnostic method for prediction of pT0. However, despite the use of this diagnostic method, residual cancer after RP was found in 3 patients. Therefore, in patients with IPCa who have an invisible lesion on mpMRI, and who exhibit PSA density ≤0.08 after BPH surgery, if no operation is performed, active surveillance is necessary. In addition, biopsy of suspicious lesions on mpMRI after BPH surgery may be a good choice.

Our study has several limitations. First, this was a retrospective review of data from patients treated at a single institution; therefore, multi-center, prospective studies are needed. If we conduct a multi-center study and collect more cases, we may be able to generate a nomogram for residual tumors in patients with IPCa [25]. Second, prostate biopsy was performed
simultaneously with BPH surgery for 35 patients enrolled this study. Therefore, there were images of prostate biopsy hemorrhage in postoperative mpMRI. This might have caused the image quality to deteriorate [26]. However, we consulted with radiologists and confirmed that this did not limit interpretation of the image [27]. From 2006 to 2009, patients did not undergo DWI and ADC as part of mpMRI. In consultation with radiologists at our institution, we reviewed suspicious lesions and re-read them on the basis of PIRADS V2 recommendations. There were 38 patients from 2006 to 2009, and 57 patients from 2010 to the end of the study period. There was no significant difference with regard to suspicious lesions in the accuracy of mpMRI between the two groups (Group 1 from 2006 to 2009: AUC 0.764, Group 2 beyond 2010: AUC 0.774).

Despite these limitations, our study remains informative for clinicians who treat patients with IPCa. With regard to the strengths of our study, to the best of our knowledge, this is the first investigation to include mpMRI of IPCa for prediction of pT0. Furthermore, we investigated long-term follow up oncologic outcomes of IPCa with an established protocol. No patients were treated with adjuvant androgen deprivation therapy or radiotherapy until BCR; this allowed us to observe the natural history of BCR after RP. In this study, we determined the oncologic outcome according to the presence of residual tumor in IPCa. Because the oncologic outcome of IPCa patients who exhibit pT0 is good, it is important to predict pT0 where possible. Therefore, we believe that the proposed diagnostic tool is a method to reduce overtreatment in pT0 patients. We believe that our study will help clinicians to determine the direction of treatment in IPCa.

**Conclusions**

Our results demonstrate that patients with pT0 in IPCa showed a good prognosis; therefore, radical treatment may constitute overtreatment. In our study, lesions invisible on mpMRI,
Fig 2. Receiver operating characteristic curves of MRI, PSA density, and MRI combined with PSA density for predicting the presence of residual tumor (pT0).

https://doi.org/10.1371/journal.pone.0210037.g002

Table 4. Diagnostic accuracy for pT0 of mpMRI and PSA density after BPH surgery.

|                              | Residual tumor | No residual tumor (pT0) |
|------------------------------|----------------|-------------------------|
| **A**                        |                |                         |
| PSA density                  |                |                         |
| \(\leq0.08\)                 | 44 cases       | 28 cases                |
| \(>0.08\)                    | 23 cases       | 0 cases                 |
| Suspicious lesion on MRI     |                |                         |
| Yes                          | 43 cases       | 3 cases                 |
| No                           | 24 cases       | 25 cases                |
| Suspicious lesion on MRI     |                |                         |
| combined with PSA density    |                |                         |
| \(\leq0.08\)                 | 48 cases       | 3 cases                 |
| No                           | 19 cases       | 25 cases                |

| **B**                        |                |                         |
| Diagnostic Accuracy for pT0  |                |                         |
| Sensitivity                  | 95% CI         | Specificity             | 95% CI     | PPV  | 95% CI | NPV  | 95% CI |
| mpMRI alone                  | 64.18          | 51.5–75.5               | 89.29      | 71.8–97.7 | 93.5 | 82.9–97.7 | 51   | 42.4–59.5 |
| mpMRI combined with PSA density \(\leq0.08\) | 71.64          | 59.3–82.0               | 89.29      | 71.8–97.7 | 94.1 | 84.4–97.9 | 56.8 | 46.8–66.3 |

PSA, prostate-specific antigen; BPH, benign prostatic hyperplasia; PPV, positive predictive value, NPV, negative predictive value; CI, confidence interval

https://doi.org/10.1371/journal.pone.0210037.t004
combined with PSA density after BPH surgery, were significantly associated with pT0. Therefore, in IPCa, patients with PSA density \( \leq 0.08 \) after BPH surgery and with invisible cancer lesion on mpMRI should be considered for active surveillance.

**Author Contributions**

**Conceptualization:** Doo Yong Chung, Young Deuk Choi.

**Data curation:** Doo Yong Chung, Hyeok Jun Goh, Dong Hoon Koh, Min Seok Kim, Jong Soo Lee, Won Sik Jang.

**Investigation:** Doo Yong Chung.

**Methodology:** Doo Yong Chung.

**Project administration:** Young Deuk Choi.

**Supervision:** Young Deuk Choi.

**Validation:** Doo Yong Chung, Young Deuk Choi.

**Writing – original draft:** Doo Yong Chung.

**Writing – review & editing:** Doo Yong Chung, Hyeok Jun Goh, Young Deuk Choi.

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67: 7–30. https://doi.org/10.3322/caac.21387 PMID: 28055103

2. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 2141–2149. https://doi.org/10.1200/JCO.2004.01.062 PMID: 15169800

3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124–137. https://doi.org/10.1016/j.eururo.2013.09.046 PMID: 24207135

4. Otto B, Barbieri C, Lee R, Te AE, Kaplan SA, Robinson B, et al. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Adv Urol. 2014; 2014: 627290. https://doi.org/10.1155/2014/627290 PMID: 24876835

5. Tombal B, De Visccher L, Cosyns JP, Lorge F, Opsomer R, Wese FX, et al. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers. BJU Int. 1999; 84: 1015–1020. PMID: 10571626

6. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol. 2007; 41: 456–477. https://doi.org/10.1080/00365590701673625 PMID: 17934985

7. Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, et al. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol. 2008; 54: 118–125. https://doi.org/10.1016/j.eururo.2008.02.018 PMID: 18314255

8. Masue N, Deguchi T, Nakano M, Ebara H, Uno H, Takahashi Y. Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b. Int J Urol. 2005; 12: 1045–1049. https://doi.org/10.1111/j.1442-2042.2005.01205.x PMID: 16409608

9. Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML. Subclassification of clinical stage T1 prostate cancer; impact on biochemical recurrence following radical prostatectomy. J Urol. 2007; 178: 1277–1280; discussion 1280–1271. https://doi.org/10.1016/j.juro.2007.05.153 PMID: 17698121

10. Melchior S, Hadaschik B, Thueroff S, Thomas C, Gillitzer R, Thueroff J. Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int. 2009; 103: 1478–1481. https://doi.org/10.1111/j.1464-410X.2008.09879.x PMID: 19076194

11. Capitanio U, Briganti A, Suardi N, Gallina A, Salonia A, Freschi M, et al. When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? Int J Urol. 2011; 18: 148–153. https://doi.org/10.1111/j.1442-2042.2010.02689.x PMID: 21198944
12. Chung DY, Koh DH, Goh HJ, Kim MS, Lee JS, Jang WS, et al. Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI. BMC Cancer. 2018; 18: 1057. https://doi.org/10.1186/s12885-018-4955-8 PMID: 30382916

13. Weinreb JC, Barentzen JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging—Reporting and Data System: 2015, Version 2. Eur Urol. 2016; 69: 16–40. https://doi.org/10.1016/j.eururo.2015.08.052 PMID: 26427566

14. Barentzen JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22: 746–757. https://doi.org/10.1007/s00330-011-2377-y PMID: 22323008

15. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, et al. Prostate cancer detection with magnetic resonance-ultrasound biopsy: The role of systematic and targeted biopsies. Cancer. 2016; 122: 884–892. https://doi.org/10.1002/cncr.29874 PMID: 26749141

16. Le JD, Tan N, Shkolny E, Lu DY, Kwan L, Marks LS, et al. Multilocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015; 67: 569–576. https://doi.org/10.1016/j.eururo.2014.08.079 PMID: 25257029

17. Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Peloquin F, Desruelle J, et al. Reassessment of nonplanimetric transrectal ultrasound prostate volume estimates. Urology. 1996; 47: 857–862. https://doi.org/10.1016/S0090-4295(96)00068-4 PMID: 8677577

18. Cronin AM, Godoy G, Vickers AJ. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol. 2010; 183: 984–989. https://doi.org/10.1016/j.juro.2009.11.027 PMID: 20083281

19. Bostwick DG, Bostwick KC. ‘Vanishing’ prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004; 94: 57–58. https://doi.org/10.1111/j.1464-410X.2004.04900.x PMID: 15217431

20. Noguchi M, Noda S, Nakashima O, Kojir o M. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer. Oncol Rep. 2002; 9: 1075–1080. PMID: 12168076

21. Teber D, Cresswell J, Ates M, Erdogan T, Hruza M, Gozen AS, et al. Laparoscopic radical prostatectomy in clinical T1a and T1b prostate cancer: oncologic and functional outcomes—a matched-pair analysis. Urology. 2009; 73: 577–581. https://doi.org/10.1016/j.urology.2008.09.059 PMID: 19100598

22. Benson MC, McMahon DJ, Cooner WH, Olsson CA. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol. 1993; 11: 206–213. PMID: 7508785

23. Ciatto S, Bonardi R, Lombardi C, Cappelli G, Castagnoli A, D’Agata A, et al. Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting. Int J Blot Markers. 2001; 16: 179–182. PMID: 11605730

24. Nordstrom T, Akre O, Aly M, Gronberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018; 21: 57–63. https://doi.org/10.1038/s41391-017-0024-7 PMID: 29259293

25. van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Bohm M, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017; 120: 774–781. https://doi.org/10.1111/bju.13814 PMID: 28207981

26. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004; 183: 1079–1083. https://doi.org/10.2214/ajr.183.4.1831079 PMID: 15385308

27. Park KK, Lee SH, Lim BJ, Kim JH, Chung BH. The effects of the period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. BJU Int. 2010; 106: 1148–1151. https://doi.org/10.1111/j.1464-410X.2010.09287.x PMID: 20346052